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GJC2 Missense Mutations Cause Human Lymphedema
Robert E. Ferrell,1,4 Catherine J. Baty,2,4 Mark A. Kimak,1 Jenny M. Karlsson,2 Elizabeth C. Lawrence,1
Marlise Franke-Snyder,1 Stephen D. Meriney,3 Eleanor Feingold,1 and David N. Finegold1,4,*
Lymphedema is the clinical manifestation of defects in lymphatic structure or function. Mutations identiﬁed in genes regulating
lymphatic development result in inherited lymphedema. Nomutations have yet been identiﬁed in genes mediating lymphatic function
that result in inherited lymphedema. Survey microarray studies comparing lymphatic and blood endothelial cells identiﬁed expression
of several connexins in lymphatic endothelial cells. Additionally, gap junctions are implicated in maintaining lymphatic ﬂow.
By sequencing GJA1, GJA4, and GJC2 in a group of families with dominantly inherited lymphedema, we identiﬁed six probands with
unique missense mutations in GJC2 (encoding connexin [Cx] 47). Two larger families cosegregate lymphedema and GJC2 mutation
(LOD score ¼ 6.5). We hypothesize that missense mutations in GJC2 alter gap junction function and disrupt lymphatic ﬂow. Until
now, GJC2 mutations were only thought to cause dysmyelination, with primary expression of Cx47 limited to the central nervous
system. The identiﬁcation of GJC2mutations as a cause of primary lymphedema raises the possibility of novel gap-junction-modifying
agents as potential therapy for some forms of lymphedema.Lymphedema is the abnormal accumulation of lymphatic
ﬂuid in interstitial space. Patients with lymphedema suffer
from recurrent local infections, physical impairment, and
cosmetic and psychosocial stigmatization and may be at
increased risk for developing lymphangiosarcoma.1 The
population prevalence of lymphedema is estimated in
the range of 1.3–1.4 per 1000.2 Primary (inherited) lym-
phedema is less common than secondary lymphedema,
which is associated with conditions such as ﬁlariasis,
trauma, and cancer therapy. Recent studies in families
with inherited forms of lymphedema have identiﬁed
six genes, FLT43,4 (encoding VEGFR3) (MIM 153100),
FOXC25,6 (MIM 153400), SOX187 (MIM 607823), HGF8
(MIM 142409), MET8 (MIM 164860), and CCBE19,10
(MIM 235510), causing lymphedema.
To identify other causal genes for lymphedema, we
reviewed differential gene expression in lymphatic endo-
thelial cells (LECs) versus blood endothelial cells (BECs)
and noted that GJA1 (encoding connexin [Cx] 43) (MIM
121014) is expressed in BECs and LECs whereas GJC2
(encodingCx47) (MIM608803) is expressedonly inLECs.11
Gap junctions are intercellular channels formed by hexam-
ers of connexin proteins on adjoining cells that facilitate
the electrical andmetabolic coupling of cells within a tissue
via a varietyofmechanisms. Rhodinﬁrst suggested a role for
gap junctions on lymphatic vessels,12 but there has been
limited characterization of gap junction intercellular
communication (GJIC) in lymphatic vessels or LECs.13,14
We investigated the connexins as potential genes for
causal lymphedema mutations in the families ascertained
through the University of Pittsburgh Lymphedema Family
Study (UPLFS). This study was approved by the Institu-1Department of Human Genetics, Graduate School of Public Health, University
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The Ametional Review Board of the University of Pittsburgh, and
informed consent was obtained from all subjects. Initially,
families were ascertained by a physician’s diagnosis of lym-
phedema in the proband (conﬁrmed by medical records)
and a lymphedema occurrence in a ﬁrst-degree relative.
We screened 150 probands from the UPLFS for mutations
in GJA1 (chromosome 6q22-q23), GJA4 (chromosome
1p35.1) (MIM 121012), and GJC2 (chromosome 1q41-
q42). Sequences were aligned and curated with Sequencher
v4.7 (Gene Codes Corp.). Mutations in FLT4, FOXC2,
and SOX18, known lymphedema genes, were previously
excluded in these probands by bidirectional sequence
analysis. The sequences of GJA4 (NM002060), GJA1
(NM000165), and GJC2 (NM020435) were downloaded
from Entrez Nucleotide. Unique sequence ampliﬁcation
and sequencing primers (see Table S1 available online)
were designed to amplify genes in overlapping fragments.
These fragments were then sequenced in both directions
with ABI BigDye v3.1 chemistry, and the products were
resolved on an ABI 3730 DNA sequencer in the Genomics
and Proteomics Core Laboratory of the University of
Pittsburgh. Six lymphedema families of mixed European
ancestry were identiﬁed with heterozygous dominant
causal GJC2 mutations (Table 1).
We identiﬁed two GJC2 mutations in families suitable
for linkage analysis: one cosegregating lymphedema and
a C>T transition at nucleotide 143 leading to an S48L
(family 135) substitution in extracellular loop 1 of Cx47,
and another cosegregating lymphedema and a C>T transi-
tion at nucleotide 778 resulting in an R260C (family 168)
substitution in extracellular loop 2 (Figure 1). Linkage anal-
ysis in these two families yielded a LOD score of 6.5 underof Pittsburgh, Pittsburgh, PA 15261, USA; 2Department of Cell Biology and
USA; 3Department of Neuroscience, Faculty of Arts and Sciences, University
Genetics. All rights reserved.
rican Journal of Human Genetics 86, 943–948, June 11, 2010 943
Table 1. GJC2 Mutations Observed in Primary Lymphedema Families
Family Sequence Substitution Amino Acid Change Predicted Domain
337 AGATCCACAACC(A>C)CTCCACCTTCGT H19P N-terminal
135 GAGGCCATCTACT(C>T)GGCGGAGCAGGCC S48L Extracellular loop 1
251 CCACGCCGCGCGCCCC(G>A)GCGCACCTGCCG R125Q Intracellular loop
104 GAGGAGCCCATGCTG(G>A)GCCTGGGCGAGGAG G149S Intracellular loop
168 TGCTTCGTGTCG(C>T)GCCCTACTGAAAAG R260C Extracellular loop 2
151 CCCGCGCCGCCCC(C>T)G CCCTGCGCCTTC P316L C-terminala model of disease frequency ¼ 0.0001, penetrance ¼ 0.9,
phenocopy rate ¼ 0.0, assuming no recombination. The
R260C mutation is located within the conserved SRPTEK
motif, important for connexon docking. This motif is
a target of peptide mimetic inhibitors of GJIC for Cx43
and Cx32.15,16 Four additional unique GJC2 mutations
were observed in other, smaller families: H19P in the
N-terminal domain, R125Q in the intracellular loop,
G149S in the intracellular loop, and P316L in the
C-terminal domain were transmitted from an affected
parent to an affected child. Samples were not available
from other family members, and these cases are consistent
with, but not informative for, linkage. (Figure 2; Table 1).
GJC2mutations occur only in affected or at-risk individ-
uals, cause a change in a conserved amino acid of Cx47,
and were not present in 250 sequenced, ethnically
matched controls (0 of 500 alleles). These missense muta-
tions affect amino acids highly conserved in mammalian
evolution, showing only one variation of glycine to
alanine in the case of the G149S mutation (Figure 3).
Non-lymphedema-associated sequence variants were also
identiﬁed (Table S2).
The current age or age at death, genotype with respect to
GJC2, age at onset of lymphedema of the leg and/or hand,
and other phenotypic features in the families demon-
strating linkage are shown in Figure 1. Uncomplicated
lymphedema of the leg or hand was the only constant
feature reported in the affected individuals. Individual
IV-20, family 135, was reported to have a nuchal fold at
birth but was nonpenetrant for lymphedema. Many
affected individuals had onset of lymphedema in child-
hood or adolescence. Individuals IV-4, family 168, and
III-18, IV-19, and IV-20, family 135, were nonpenetrant
males, showing reduced penetrance of GJC2 mutations in
these families. Generally, males showed a later age at onset
than females. Other features reported in some lymphe-
dema pedigrees (ptosis, cellulitis, venous insufﬁciency,
etc.) appeared sporadically in these families. Four individ-
uals in family 135 reported recurrent skin infections. In
the four smaller families with mutations, the clinical
phenotypes were similar to the families demonstrating
linkage, including a later age at onset.
Of note, two additional rare mutations, one leading to
a truncated Cx47 protein (E44ter) and a 22 bp deletion944 The American Journal of Human Genetics 86, 943–948, June 11,leading to a truncation of the GJC2 protein at residue 30,
were identiﬁed. These changes were not present in 500
control alleles but failed to segregate with disease in
pedigrees. These early nonsense changes are predicted to
code for a prematurely truncated polypeptide, leading
to a null allele. The carriers of these truncation mutations
showed no discernable phenotype, consistent with the
Cx47-deﬁcient mouse, in which heterozygous or homozy-
gous null animals have no gross phenotype and no Cx47-
speciﬁc developmental or functional abnormality.17,18
We show here that mutations in GJC2 cause primary
lymphedema, through linkage in two families and signiﬁ-
cant genetic evidence from four independent families.
We hypothesize that coordinated gap junction function
is needed to optimize the conduction of lymph from the
periphery to the thoracic duct and is compromised in indi-
viduals with GJC2missense mutations. In vivo evidence in
rat mesenteric lymphatics shows signiﬁcant impairment
of contraction propagation upon treatment with nonspe-
ciﬁc gap junction inhibitors.13,14 The GJC2 mutations are
notable because they support an abnormality in lymphatic
function rather than the previously identiﬁed mutations
in genes causing abnormal lymphatic development.
Such functional abnormalities could potentially beneﬁt
from the current development of gap-junction-modifying
drugs,19,20 offering a novel medical treatment for lymphe-
dema.
The role of GJC2/Cx47 in lymphatic function is unex-
pected because it has a demonstrated primary role in the
central nervous system (CNS), with expression reportedly
limited to oligodendrocytes.17,21 Homozygous loss-of-
function mutations in GJC2 cause Pelizaeus-Merzbacher-
like disease (PMLD; MIM 608804), characterized by severe
CNS dysmyelination.22,23 Neither individuals affected
with PMLD nor their obligate heterozygous carriers of
GJC2 mutations are reported to have a lymphatic pheno-
type, although the clinical phenotype of lymphedema is
often subtle. Likewise, the clinical information available
on our lymphedema patients and families would be insen-
sitive to a mild clinical neurological abnormality. We
observed no mutations in the transmembrane domains
where many of the PMLD mutations are found.23
The GJC2 lymphedema mutations are distributed
throughout the protein, with no geographical clustering.2010
Figure 1. Pedigrees of the Two Linked Families
Pedigrees of the two linked families showing current age or age at death, cosegregation of GJC2missense mutation with lymphedema,
age at onset of lymphedema of the leg and/or hand, and other phenotypic features. Family 168, R260C, and family 135, S48L, are shown.
Filled shapes indicate affected individuals with lymphedema. LOD ¼ 6.5. Arrows indicates the probands.However, the two mutations located in the extracellular
loop domains (i.e., S48L and R260C) are predicted to inter-
fere with connexon (i.e., hemichannel) assembly into
functional channels. The linked R260Cmutation is located
in a conserved SRPTEK motif important for connexon
docking; the importance of this motif is further under-
scored by a homologous autosomal-dominant GJA1muta-
tion (R202H) identiﬁed in families with oculodentodigital
dysplasia (MIM 164200), with functional characteristics
of poor plaque formation and impaired dye transfer andThe Ameelectrical coupling.24,25 Similarly, we expect these two
extracellular mutations to result in impaired channel
activity and propose that this might result in impaired
coordination of pulsatile lymphatic ﬂow.14 The mecha-
nism through which the identiﬁed intracellular mutations
mediate their effects is not clear, especially in light of the
more recent recognition that connexin function is not
limited only to their well-recognized channel activity but
may involve hemichannel function or changes in cell
adhesion or motility.26–29 Further characterization of therican Journal of Human Genetics 86, 943–948, June 11, 2010 945
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Figure 2. Schematic Drawing of Con-
nexin 47 Protein Locating Lymphedema-
Associated Amino Acid Substitutions
Domain break points and sequence are
as described by Uhlenberg et al.22 and
http://www.uniprot.org/uniprot/Q5T442.mutations reported here, especially with regard to their
predicted dominant-negative effect with wild-type Cx47
or transdominant effect with other endogenous connexinsFigure 3. Amino Acid Alignment of Cx47 from Different Species
Tan indicates intracellular domains; green indicates transmembrane domains; white indicate
the positions of amino acids altered in lymphedema families.
946 The American Journal of Human Genetics 86, 943–948, June 11, 2010expressed in LECs, will contribute to
our understanding of the role of con-
nexins in lymphatic function.
Although we are approaching the
400th anniversary of the ﬁrst descrip-
tion of the lymphatic system in
1627,30 lymphatics remain a poorly
understood and largely neglected bio-
logical system. Despite an essential
and active role in the maintenance
of ﬂuid homeostasis, trafﬁcking of
antigen-presenting and other immune
cells, and pathological processes like
chronic inﬂammation and cancer,
the lymphatic vascular system is often
viewed as a passive conduit rather
than an interactive participant in
these processes. The identiﬁcation of
mutations in the Cx gene family in
primary lymphedema justiﬁes furtherinvestigation into the manipulation of gap-junction-coor-
dinated lymphatic ﬂow and function as a possible thera-
peutic option for primary lymphedema.s extracellular domains. Red dots represent
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